2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2484

Hepatic Steatosis in Rheumatoid Arthritis: Associations with Disease Characteristics, Pharmacotherapies, and Atherosclerosis
Abstract Number: 2490

Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 1519

Heterogeneous Nuclear RNP-K Is a Novel Cold-Related Autoantigen in Patients with Raynaud’s Phenomenon
Abstract Number: 1330

High Body Mass Index Is Associated with Decreased Response to Initial Combination Therapy in Recent Onset RA Patients
Abstract Number: 1031

High Degree of Symmetricity of MRI-Detected Articular Tissue Damage in Subjects with Knee Pain: A within-Person Analysis From the JOG Study
Abstract Number: L2

High Dose Immunoablation and Autologous Hematopoietic Stem Cell Transplantation Versus Monthly Intravenous Pulse Therapy Cyclophosphamide in Severe Systemic Sclerosis
Abstract Number: 1203

High Expression of Genes in the Toll-Like Receptor and Interferon Pathways Are Associated with Radiographic Damage in African-Americans with ACPA-Positive RA
Abstract Number: 2380

High Frequency of Ferritin Autoantibodies in Takayasu Arteritis
Abstract Number: 1256

High Inflammation May Condition the Antiatherogenic Function of Small, Dense HDL in Patients with Active Rheumatoid Arthritis
Abstract Number: 2089

High Local Cathepsin Activity in a Murine Rheumatoid Arthritis Model, but Not in an Osteoarthritis Model, Explains the Difference in Cartilage Vdipen Neoepitope Formation
Abstract Number: 2393

High Mobility Group Box 1 Levels Are Not Associated with Subclinical Carotid Atherosclerosis in Patients with Granulomatosis with Polyangiitis but Are Reduced by Glucocorticoids and Statins
Abstract Number: 400

High Patient Global Assessment Scores Associate with the Residual Disease Activity Unidentified by a 28-Joint Examination in Rheumatoid Arthritis Patients Approaching Clinical Remission
Abstract Number: 223

High Prevalence and Clustering Over Time of Anti-PL-7 Autoantibody-Positive Idiopathic Inflammatory Myopathies
Abstract Number: 586

High Prevalence of Anti-CD-74 Antibodies with Specificity for the Class II-Associated Invariant Chain Peptide in Patients with Axial Spondyloarthritis but Not in Controls
Abstract Number: 2026

High Prevalence of Cervical Spine and Temporomandibular Joint Involvement in Patients with Juvenile Idiopathic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].